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AntiplateletAbstract Some new diorganoantimony(III) and triorganoantimony(V) compounds of Schiff bases
derived from amino acids having the general formula Ph2Sb[OC(R)CHC(R
0)NC(Y) COOH] [where
R = CH3, R
0 =C6H5, Y = AH2CH2(1), HCH2C6H5(2); R = R0 =C6H5, Y = AH2CH2(3),
AHCH2C6H5(4)] have been synthesized by the reaction of Ph3Sb with RC (O) CHC(R0) NHC(Y)
COOH in 1:1 M ratio. Whereas Ph3Sb[OC(R)CHC(R
0)NC(Y) COOH]2 (where R = CH3, R0 =
C6H5, Y = AH2CH2(5), R = R0 =C6H5, Y = AHCH2C6H5(6)) have been synthesized by the
reactions of Ph3SbBr2 with Na [OC(R) CHC(R
0)NC(Y) COOH] in 1:2 M ratio, respectively in
anhydrous benzene. All these compounds have been characterized by elemental analyses and molec-
ular weight measurement. Probable structures of these compounds have been proposed on the basis
of spectral studies (I.R. 1H and 13C NMR). Schiff base (R = CH3 R
0 =C6H5, Y = AH2CH2) and
its corresponding organoantimony(III) and -antimony(V) compounds have been screened for
antimicrobial, antioxidant and antiplatelet activities. These synthesized compounds can be used
as new class of antimicrobial, antioxidant and antiplatelet agents with potential for clinical
development.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Bioorganometallic chemistry is dedicated to the study of
biological applications of organometallic compounds with a
view to design new drugs offering better performance than
those already known. In recent years, the chemistry of organ-
oantimony derivatives continues to attract the attention due to
wide structural diversities [1–4]. In addition to this organoan-
timony compounds have shown a number of biological
68 R. Gupta et al.activities such as antitumor [5,6], antimicrobial [7,8] and anti-
spermatogenic [9–10]. Schiff bases derived from amino acid
behave as unidentate [11], bidentate [12] or bridging ligands
[13] in their metal complexes. These ligands demonstrate not
only a remarkable diversity in their structure, but also exhibit
interesting biocidal activities [14–16]. We have reported organ-
oantimony complexes in +3 and +5 oxidation state of Schiff
bases [17,18] derived from amino alcohols, but organoantimo-
ny(III) and -antimony(V) derivatives of Schiff bases derived
from amino acids have not been reported so far. In the present
investigation we report the synthesis, spectroscopic analysis,
and antimicrobial, antioxidant and antiplatelet activities of
organoantimony(III) and -antimony(V) compounds of Schiff
base derived from amino acids. Blood platelets are involved
in hemostasis. The normal hemostatic system limits blood loss
by precisely regulating interactions between components of
vessel wall, circulating blood platelets and plasma proteins.
Platelets can adhere to the walls of the blood vessels, release
bioreactive compounds and then aggregate to each other.
These properties increase to a well established level under con-
ditions of arterial thrombosis and atherogenesis that may
cause life-threatening disorders such as unstable angina, heart
attack and reclusions after angioplasty [19]. Therefore, inhibi-
tion of platelet aggregation is important in the prevention and
treatment of cardiovascular diseases [20].
2. Experimental
2.1. Materials
Solvents were dried by standard methods [21] before use.
Ph3Sb(Aldrich) has been used as supplied. Ph3SbBr2 [22]
and Schiff bases [12] have been prepared by literature
methods. Antimony was estimated by iodometric method
[23].Table 1 Synthetic and analytical data of diphenylantimony(III) an
amino acids.
S.No Na Reactants (g)
RC (O) CHC(R0)
NHC(Y) COOH
Ph3Sb Ph3SbBr2 Pro
1 – R = CH3, R
0 =C6H5,
Y = AH2CH2
0.95
1.43 – C25
82%
2 – R= CH3, R
0 =C6H5,
Y = AHCH2C6H5
1.02
1.16 – C31
85%
3 – R= R0 =C6H5,
Y = AH2CH2
1.12
1.34 – C30
88%
4 – R= R0 =C6H5,
Y = A HCH2C6H5
1.10
1.04 C36
80%
5 0.11 R = CH3, R
0 =C6H5,
Y = A H2CH2
1.01
– 1.22 C44
80%
6 0.12 R = R0 =C6H5,
Y = AHCH2C6H5
1.21
– 1.33 C56
83%2.2. Physical measurements
1H and 13C NMR spectra in CDCI3 solution were recorded
with a JEOL-FT Al 300 MHz Spectrometer using TMS an
internal reference. IR spectra were recorded on an 8400 s Shi-
madzu FT-IR Spectrophotometer as Nujol mull on KBr cells
in the range 4000–400 cm1. Elements (C, H and N) were
recorded on a Perkin Elmer-2400 C, H, N analyzer. Molecular
weights were determined cryoscopically in freezing benzene
solution using a Beckmann’s thermometer. Since diorganoanti-
mony(III) and triorganoantimony(V) derivatives have been
synthesized by different methods we have given here the synthe-
sis of one compound of each series in detail. The synthetic and
analytical data of analogous have been summarized in Table 1.
2.3. Synthesis of diphenylantimony(III) derivatives
Ph2Sb[OC(CH3)CHC(C6H5) NCH2CH2 COOH]
A benzene solution of Schiff base [CH3C(O) CHC (C6H5)
NHCH2CH2COOH] [0.95 g 4.07 mM] was added to benzene
solution of Ph3Sb [1.43 g 4.05 mM] in 1:1 M ratio. The reac-
tion mixture was reﬂuxed for 4 h. After the completion of
reaction, the excess solvent was removed under reduced
pressure to yield colored viscous product (yield 82%). It was
puriﬁed by benzene/n-hexane mixture. The analytical results
are presented in Table 1.
2.4. Synthesis of triphenylantimony(V) derivatives
Ph3Sb[OC(CH3)CHC(C6H5) NCH2CH2COOH]2
A benzene solution of Schiff base[CH3C(O) CHC (C6H5)
NHCH2CH2COOH] (1.01 g 4.33 mM) was added to the
sodium methoxide solution obtained by the interaction of
sodium (0.11 g, 4.78 mM) with methanol, and the reactiond triphenylantimony(V) complexes of Schiff base derived from
duct % yield Elemental analyses
found
(Calcd.)
Mol. Wt. Found
(Calcd.)
C H N Sb
H24O3NSb 59.00
(59.08)
4.12
(4.72)
2.12
(2.75)
20.00
(23.97)
490
(507.75)
H28O3NSb 63.12
(63.72)
4.72
(4.71)
2.00
(2.39)
19.23
(20.85)
570.00
(583.75)
H26O3NSb 62.90
(63.18)
4.00
(4.56)
2.12
(2.45)
19.82
(21.36)
550.00
(569.75)
H30O3NSb 66.12
(66.89)
4.23
(4.64)
1.92
(2.16)
17.92
(18.85)
600.00
(645.75)
H43O6N2Sb 64.00
(64.64)
5.18
(5.26)
3.12
(3.42)
14.18
(14.90)
790.00
(816.81)
H51O6N2Sb 68.96
(69.36)
5.20
(5.26)
2.13
(2.89)
12.00
(12.56)
920.00
(968.75)
Pharmacological activities of organoantimony compounds 69mixture reﬂuxed for 3 h. The benzene solution of tripheny-
lantimony(V) dibromide [1.22 g 2.38 mM] was added to the
above reaction mixture after cooling. The reaction mixture
was reﬂuxed for 4 h and the precipitated NaCl was ﬁltered
off. The removal of volatile components from the ﬁltrate under
reduced pressure yields a dark brown viscous liquid. It was
puriﬁed by benzene/n-hexane mixture. The analytical results
are presented in Table 1.
2.5. Antioxidant activities
2.5.1. FRAP assay (ferric reducing ability of plasma)
The method was performed by the established protocol with
some modiﬁcations [24].
2.5.1.1. Procedure. Chemical compounds (1 g) were mashed
with a cool mortar and pestle using quartz sand and 9 mL cool
0.1 M phosphate buffer was added (pH 7.6, containing
0.1 mM EDTA). This mixture was ﬁltered through a ﬁlter
paper and centrifuged at 15,000 rpm for 10 min. The superna-
tant was used for the measurements. The volume was made up
to 5 mL and O.D. was taken at 593 nm.
2.5.1.2. Calculation. The relative activities of samples were
assessed by comparing their activities standard curve of ferrous
sulfate.
2.6. Antimicrobial activity
Antimicrobial activity of chemically derived compounds was
studied. Four bacterial and fungal strains were selected for
the primary screening.
2.6.1. Microorganisms used
Clinical laboratory bacterial isolates of Bacillus subtilis, Staph-
ylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli
and fungal isolates viz. Aspergillus niger, Penicillium funicu-
losum, Trichoderma reesei and Fusarium oxysporum were col-
lected from the stock cultures of Microbiology Laboratory,
SMS Medical College, Jaipur, India.
2.6.2. Preparation of samples
The 10 mg/mL of samples was dissolved in DMSO and further
dilutions were made for calculating MIC value.
2.6.3. Culture and maintenance of bacteria
Pure cultures obtained from SMS Medical College, Jaipur,
India were used as indicator organisms. These bacteria were
grown in Nutrient agar medium (prepared by autoclaving 8%
Nutrient agar of Difco-Laboratories, Detroit, USA, in distilled
water at 15 lbs psi for 25–30 min) by incubating at 37 C for
48 h. Each bacterial culture was further maintained on the same
medium after every 48 h of transferring. A fresh suspension of
test organism in saline solution was prepared from a freshly
grown agar slant before every antimicrobial assay.
2.6.4. Determination of antibacterial assay
In vitro antibacterial activity of the samples Gram positive and
Gram negative bacterial strains was evaluated by the agar well
diffusion method [25]. The Mueller Hinton agar was melted
and cooled to 48–50 C and a standardized inoculum(1.5 · 108 CFU/mL, 0.5 McFarland) was then inoculated
aseptically to the molten agar and poured into sterile petri
dishes to obtain a solid medium. Wells were prepared in the
seeded agar plates. The test compound (100 lL) was intro-
duced into the well (6 mm). The plates were incubated over-
night at 37 C. The antimicrobial spectrum of the chemical
compounds was determined for the bacterial species in terms
of zone sizes around each well. The diameters of zone of inhi-
bition produced by the agent were compared with those pro-
duced by the commercial control antibiotics, streptomycin.
The control zones were subtracted from the test zones and
the resulting zone diameter was measured with antibiotic zone
reader to nearest mm. The experiment was performed three
times to minimize the error and the mean values are presented.
2.6.5. Determination of antifungal assay
Antifungal activity of the experimental plant was investigated
by agar well diffusion method [26]. The yeasts and saprophytic
fungi were subcultured onto Sabouraud dextrose agar, SDA
(Merck, Germany) and respectively incubated at 37 C for
24 h and 25 C for 2–5 days. Suspensions of fungal spores were
prepared in sterile PBS and adjusted to a concentration of
106 cells/mL. The plates were dried at room temperature for
15 min. Wells of 10 mm in diameter and about 7 mm apart
were punctured in the culture media using a sterile glass tube.
0.1 ml of several dilutions of fresh chemical compounds was
administered to fullness to each well. The plates were incu-
bated at 37 C. After incubation for 24 h bioactivities were
determined by measuring the diameter of inhibition zone (in
mm). All experiments were made in triplicate and means were
calculated.
2.7. Antiplatelet activity
2.7.1. Preparation of extract
Methanolic (met OH 50%) and aqueous extracts were
obtained by macerating 1 g of chemical compounds separately,
kept on a rotary shaker for 24 h. The extract was ﬁltered, cen-
trifuged at 5000 rpm for 15 min and was dried under reduced
pressure. The extract was diluted to different concentrations
and stored at 4 C in airtight bottles. Blood samples were col-
lected from SMSMedical College, Jaipur and subjected to cen-
trifugation at 10,000 rpm for 5.5 min. 0.2 mL platelet rich
plasma was taken from the sample and dissolved in isotonic
CaCl2. Various hemostatic parameters; prothrombin time
(PT) and activated partial thromboplastin time (APTT) were
measured. Amelung/Sigma Amax CS400 Coagulant Analyzer,
New York, USA was used for the experimental work.
2.7.2. Determination of PT
2.7.2.1. Principle. The coagulation process gets triggered by
incubation of plasma with the optimum amount of thrombo-
plastin and calcium. The time to formation of a ﬁbrin clot is
then measured.
2.7.2.2. Procedure. 1 part of sodium citrate (0.11 mol L1) with
9 parts of venous blood was mixed with care and formation of
foam was avoided. The blood specimen was centrifuged at
1500 rpm for 15 min at room temperature and stored in a
capped tube at room temperature for not more than 5 min.
Plasma was tested within 24 h of blood collection. 100 lL of
70 R. Gupta et al.citrated plasma samples was pipetted into a pre sterilized test
tube at room temperature and different concentrations of
chemical compounds (100–2000 lg mL1) were added. Stop
watch was used on the coagulation analyzer to determine the
coagulation time.
2.7.3. Determination of APTT
2.7.3.1. Principle. The deﬁciency of one or the more clotting
factors of the intrinsic pathway and also the presence of hepa-
rin (coagulation inhibitor) prolong APTT of the plasma. The
time taken for the clot to form is measured and used to deter-
mine the anticoagulant status.
2.7.3.2. Procedure. Fresh plasma was used for the entire tests
because it performed best when tested immediately after collec-
tion as compared to stored plasma. 9 parts of whole blood
from veins was poured into a clean test tube containing 1 part
of TSC solution (3.2% buffered tri-sodium citrate solution)
and mixed immediately with an anticoagulant to avoid foam
formation. Later, it was centrifuged for 15 min at 3000 rpm
and the plasma was collected in separate test tubes. Hemo-
lyzed, lipaemic turbid samples were avoided. APTT reagent
was added gently swirling before use. 100 lL each of APTT
reagent and 0.025 mol L1 CaCl2 reagent which was used as
standard, was pipetted into separate test tubes and incubated
in a water bath at 37 C for 3 min. After 3 min, 100 lL of well
mixed CaCl2 reagent was added to the 37 C maintained tem-
perature test tube containing APTT reagent and plasma and
simultaneously the stop watch was started. The contents of
the tube were mixed back and forth and the stopwatch was
put to stop as soon as ﬁbrin strand was visible through high
powered lens in a coagulation analyzer that initiated gel clot
formation. The time taken for clot formation was measured
to the nearest 0.1 s. Thus the APTT value was calculated in
seconds. The control was also run in parallel where chemical
compounds in different concentrations (100–2000 lg mL1)
were added replacing the APTT reagent to evaluate the APTT
activity of the test samples [27].
3. Results and discussion
Diphenylantimony(III) derivatives of Schiff bases have been
synthesized by the reactions of triphenylantimony with Schiff
base in benzene solution.Table 2 1H NMR data (in ppm) of diphenylantimony (III) and trip
acids.
S.No. Complexes CH3
1 1.98 (s)
2 1.98 (s)
3 –
4 –
5 2.0 (s)
6 –
d, doublet; t, triplet; m, multiplet.Ph3SbþRC ðOÞ CHCðR0Þ NHCðYÞ
COOH!C6H6 Ph2Sb½OCðRÞ CHCðR0Þ N C ðYÞCOOH þ C6H6
where R = CH3, R
0 =C6H5, Y = AH2CH2(1), AHCH2C6H5
(2); R = R0 =C6H5, Y = AH2CH2(3) AHCH2C6H5 (4)].
Reactions of Ph3SbBr2 with the sodium salt of Schiff base
in 1:2 M ratio in reﬂuxing benzene gave corresponding organ-
oantimony(V) derivatives:
Ph3SbBr2þ2Na½OCðRÞCHCðR0ÞNC ðYÞ
COOH!C6H6 Ph3Sb½OCðRÞCHCðR0ÞNCðYÞCOOH2þ2NaBr
where R = CH3, R
0 =C6H5, Y = AH2CH2,(5) A R=
R0 =C6H5, Y = AHCH2C6H5 (6)]
All these compounds are colored viscous liquids or solids.
These compounds are soluble in common organic solvents
and monomeric in nature.3.1. I.R. spectra
The mast spectra of one of the representative compounds of
both the series i.e. Ph2Sb[OC (CH3) CHC (C6H5) N CH2
CH2 COOH] and Ph3Sb[OC (CH3) CHC (C6H5) N CH2
CH2 COOH]3 have been recorded which exhibit molecular
ion peaks at m/z 508 and 832.
Disappearance of m NH band observed at 2870–2890 cm1
in the spectra of ligands and appearance of a new band in the
range 450–475 cm1 for m Sb–N [28] indicate the deprotona-
tion of the N–H group and the formation of antimony nitro-
gen bond. The intense absorption bands observed in the
spectra of free ligands in the regions 1600–1610 cm1 and
1560–1570 cm1 have been assigned to m C‚N [29] and m
C‚O, respectively. These bands are shifted to a lower wave
number in the spectra of their corresponding diphenylantimo-
ny(III) and triphenylantimony(V) compounds. This indicates
the involvement of these groups in bonding. The presence of
another band in the region 500–550 cm1 due to SbAO [30]
conﬁrmed the chelation. A medium intensity band due to m
CO (Carboxylic group) has been observed in the region
1700–1710 cm1 in the spectra of free ligands as well as their
corresponding diphenylantimony(III) and triphenlyantimo-
ny(V) derivatives. This indicates that the group of
ACOOH is not involved in bonding.henylantimony(V) complexes of Schiff base derived from amino
CH2 CH C6H5 COOH
a, 3.5 (t),
b, 2.3 (t),
5.5 (s) 7.06–7.49 (m) 11.2 (s)
2.6 (d), a, 5.3 (s),
b, 3.2 (t),
7.01–7.39 (m) 11.5 (s)
a, 3.6 (t),
b, 2.4 (t),
5.6 (s) 7.02–7.63 (m) 11.5 (s)
2.4 (d), a, 5.5(s),
b, 3.2 (t),
7.01–7.39 (m) 11.5 (s)
a, 3.9 (t),
b, 2.4 (t),
6.0 (s) 7.18–8.21 (m) 11.5 (s)
3.0 (d), a, 5.6(s)
b, 3.8(t),
7.18–8.09 (m) 11.5 (s)
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Absence of NH signal from the spectra of their corresponding
diphenylantimony(III) and triphenylantimony(V) compounds
(Table 2) indicates the complexation of antimony with Schiff
bases through SbAN bond. A small down ﬁeld shift in the
position of alkyl proton signal may be due to the delocaliza-
tion of electrons in the quasiaromatic chelate ring. A sharp sin-
glet observed at d 11.2–11.5 has been assigned to COOH group
proton in the spectra of Schiff bases and their corresponding
organoantimony(III) and -antimony(V) compounds. Presence
of carboxylic proton signal rules out the possibility of involve-
ment of this group in bonding during the complexation. The
protons of the aromatic ring appear as a complex pattern at
d 7.01–7.49 in diphenylantimony(III) compounds and at d
7.18–8.21 in triphenylantimony(V) compounds respectively.
3.3. 13C NMR
A comparison of 13C NMR spectra of metal derivatives
(Table 3) with those of the corresponding Schiff base ligand
shows a small down ﬁeld shift for >C‚0 and AC‚N groups,
indicating the involvement of these groups in bonding. The
ACOOH carbon signal was observed at 174.2–175.2 ppm in
the spectra of all these derivatives. This carbon signal does
not show any shift, which indicates the non involvement of this
group in bonding. Signals for phenyl carbons are observed at d
126.2–140.1 in diphenylantimony(III) compounds and d 127.1–
141.2 in triphenylantimony(V) compounds. In view of the pos-
sibility of dp–pp conjugation between phenyl rings and anti-
mony atom, the corrected chemical shift [31] value of phenyl
rings has been calculated by the relation d0 = d CP  d Cm
[where d Cp and d Cm are the chemical shift values of para
and meta carbons of the ring]. The d0 values for diphenylanti-
mony(III) and triphenylantimony(V) compounds are found
to be negative in the range of d 2.0 to 1.2 and d 3.1 to
2.5, respectively. Hammett Taft constant [32] of these com-
plexes is also found to be negative in the range of d 0.05 to
0.09 and d 0.14 to 1.21, respectively indicating the poor
donor capability of antimony atom.
3.4. Structure
On the basis of above spectroscopic studies, disappearance
of the signal for NH group, a shift in the position of
C‚O and CAN groups and appearance of ACOOH group
signal without any shift indicate the bidentate nature ofFigure 1 Diphenylantimony(III) compound.
Figure 2 Triphenylantimony(V) compound.
Table 4 Antioxidant potential of ligand and its corresponding
diphenylantimony(III) and triphenylantimony(V) compounds.
Compounds FRAP value (mM/g)
Free ligand 580
Organoantimony(III) compound(I) 650
Organoantimony(V) compound(5) 710
72 R. Gupta et al.Schiff bases. The monomeric nature, the presence of two
phenyl groups and one bidentate ligand indicate a trigonal
bipyramidal geometry around antimony(III) atom in com-
pounds Ph2Sb[OC(R) CHC(R
0) NC (Y) COOH] (Fig. 1)Table 5 Antmicrobial potential of ligand and its corresponding dip
Compounds Microorganisms
R1
(free Ligand)
E. coli
Pseudomonas aeruginosa
Bacillus subtilis
Staphylococcus aureus
R2
Organoantimony(V) compound
E. coli
Pseudomonas aeruginosa
Bacillus subtilis
Staphylococcus aureus
R3
Organoantimony(III) compound
E. coli
Pseudomonas aeruginosa
Bacillus subtilis
Staphylococcus aureus
R1
(free ligand)
Aspergillus niger
Penicillium funiculosum
Fusarium oxysporum
Trichoderma reesei
R2
Organoantimony(V) compound
Aspergillus niger
Penicillium funiculosum
Fusarium oxysporum
Trichoderma reesei
R3
Organoantimony(III) compound
Aspergillus niger
Penicillium funiculosum
Fusarium oxysporum
Trichoderma reesei
Streptomycin (for bacteria) – Inhibition zone – 20 mm.
Ketokenazole (for fungi) – Inhibition zone – 22 mm. *Standard.Whereas in triphenylantimony(V) complexes (Fig. 2), in
view of the presence of two bidentate chelate rings, three phe-
nyl groups and monomeric nature of these complexes, the fol-
lowing structure is being proposed in which central antimony
atom acquires pentagonal bipyramidal geometry.
3.5. Antioxidant activity
The FRAP is a simple assay that gives fast reproducible results
[33]. In this assay the antioxidant activity is measured based on
the ability to reduce ferric ion to ferrous ion and the results
were expressed as mol ferrous ion equivalent per gram of sam-
ple. Free ligand and its organoantimony(III) compound(1) and
-antimony(V) compound(5) were tested for antioxidant activ-
ity AE ranged from 500 to 750 mM/g (Table 4). Highest activ-
ity was observed in compound(5) and lowest in free ligand.
This shows that the presence of metallic moiety increases the
antioxidant activity of ligand because their proton donor
capacity was enhanced.
3.6. Antimicrobial activity
When various bacterial strains were tested against the com-
pounds they showed some potent activity. When organoanti-
mony(III) compound was tested maximum zone was observed
against E. coli at 800 ppm while staphylococcus was found to
be resistant partially. It did not show any activity at 600 ppm
against P. aeruginosa. Against B. subtilis it showed maximum
zone at 1000 ppm. However when organoantimony(V)henylantimony(III) and triphenylantimony(V) compounds.
600 ppm 800 ppm 1000 ppm
20 24 22
nil 12 14
10 10 20
nil 4 6
24 26 24
nil nil 8
20 22 22
20 20 22
22 20 24
22 24 26
nil Nil 6
Nil Nil Nil
24 20 30
nil nil nil
nil nil nil
nil nil nil
nil nil nil
14 18 24
20 24 32
14 22 28
nil nil nil
20 22 30
12 14 18
8 10 1
Figure 3 Antifungal activity of triphenylantimony(V)
compound.
Figure 4 Antibacterial activity of triphenylantimony(V)
compound.
Table 6 Clotting time of ligand and its corresponding diphenyla
prothrombin time (PT).
Extracts (aqueous fraction) Control Clotting time in seconds
PT assay
100 250 500 750 10
R1 200 228 282 300 30
s* 13.3 15.2 18.8 20 20
**c 5.4 6.16 7.6 8.24 8.
R2 90 290 320 390 384 42
s* 19.3 21.3 26 25.6 28
**c 3.2 3.5 4.3 4.26 4.
R3 268 288 310 352 36
s* 17.8 19.2 20.6 23.4 24
**c 2.9 3.2 3.4 3.9 4
Standard value for PT [plasma + thromborel (PT reagent); 1:2] = 15 s C
* s times higher than standard.
** c times higher than control.
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E. coli at 800 ppmwhile P. aeruginosawas found to be resistant,
but against B. subtilis and S. aureus the scenario was almost the
same. When free ligand is tested no zone was observed against
S. aureus. Among all the compounds tested maximum potency
was exhibited by organoantimony(V) compound (5) against
E. coli (Table 5).
Against various fungal strains when free ligand was tested,
it was observed that all fungal strains were found to be resis-
tant except A. niger while was just the opposite scenario as
observed in organoantimony(V) compound. It gave maximum
zone against F. oxysporum. Organoantimony(III) compound
gave maximum zone against P. funiculosum while A. niger
was found to be resistant against it. Overall maximum potency
was observed in organoantimony(V) compound against F.
oxysporum (Figs. 3 and 4).
3.7. Antiplatelet activity
3.7.1. Thrombin time (PT)
All the extracts prolonged the clotting time as compared to
control. In general, the activity was higher in aqueous extracts.
Signiﬁcant activity was observed at 100 lg mL1 (19.3 times),
which increased slowly up to 500 lg mL1 (26 times) and
maximum at 1000 lg mL1 (28 times) as compared to the
standard. All the compounds prolonged the clotting time as
compared to standard and control run in parallel (Table 6).
The activity was highly signiﬁcant over both standard and
control in all the cases.
3.7.2. Activated partial thromboplastin time (APTT)
All the extracts prolonged the clotting time in terms of APTT as
compared to control (+CaCl2) and standard run in parallel
(Table 7). The aqueous fractions were found to be more potent
in triorganoantimony(V) compound. The APTT activity was
higher in aqueous extract of triorganoantimony(V) compound
(9 and 10.75 times higher at 500 and 1000 lg mL1,
respectively) than other compounds in comparison to standard
and control run parallel. The aqueous extracts of chemicalntimony(III) and triphenylantimony(V) compounds assayed by
Standard PT (Plasma + PT reagent)
00 1500 2000 (lg mL1)
5 308 308
.3 20.5 20.5
26 8.26 8.26
0 423 424 15
28.2 28.2
66 4.70 4.70
0 361 362
24 24.1
4.1 4.1
ontrol = (plasma + distilled water).
Table 7 Clotting time of ligand and its corresponding diphenylantimony(III) and triphenylantimony(V) compounds assayed by
activated partial prothrombin time (APPT).
Extracts (aqueous fraction) Control Clotting time in seconds Standard PT (Plasma + PT reagent)
PT assay
100 250 500 750 1000 1500 2000 (lg mL1)
R1 20.1 25.5 32 39.8 42.5 47 47
s* 0.50 0.63 0.8 0.99 1.06 1.17 1.17
**c 0.42 0.54 0.68 0.84 0.90 1.00 1.00
R2 70 280 292 320 343 360 362 362.5 40
s* 7.0 7.3 8.0 8.5 9.0 9.05 9.05
**c 4 4.17 4.57 4.90 5.14 5.15 5.15
R3 220 228 340 389 430 438.3 438.5
s* 5.5 5.7 8.5 9.7 10.75 10.9 10.9
**c 3.14 3.25 4.85 5.5 6.14 6.26 6.26
Standard value for APPT [plasma + activated cephaloplastin (APPT reagent); 1:1:1] = 15 s Control = (plasma + distilled water + Cacl2).
* s times higher than standard.
** c times higher than control.
74 R. Gupta et al.compounds prolonged the clotting time maximum up to 430
and 362 s (+10.75- and 9-fold higher), respectively at
1000 lg mL1 and remained marginally at par on further
increase in dose concentration.
During the initial stage of thrombosis, damage in blood
vessels causes the production of adhesive proteins and soluble
agonists at the injury site. This event then stimulates platelet
adhesion, activation and aggregation, resulting in the forma-
tion of a platelet-rich thrombus [34]. Activated platelets facili-
tate thrombin formation by providing a catalytic surface on
which coagulation activation can occur. Thrombin not only
is responsible for the formation of ﬁbrin but also acts as an
extreme platelet activator. The growing aggregation of acti-
vated platelets is eventually stabilized by cross-linked ﬁbrin
and results in the formation of a platelet-rich thrombus [35].
Increased platelet aggregation (PA), as a result of increased
platelet sensitivity to agonists in vivo, contributes to the initia-
tion and progression of atherosclerosis and occurrence of
thrombotic events [36]. Platelet aggregation, which is associ-
ated with an increased release of reactive oxidative species
[27] and platelet-vessel wall interactions [37] results in damage
to the vascular endothelium [38].
4. Conclusion
A comparison of these diphenylantimony(III) and triphenylan-
timony(V) compounds showed that the coordination pattern
of ligand in both cases remains the same. Strong electron
attracting tendency of antimony in +5 oxidation state is
reﬂected by more downﬁeld shift of >C‚O and >C‚N
carbons in 13C NMR spectra. The rR and d0 values for
triphenylantimony(V) complexes are more negative than diph-
enylantimony(III) complexes, which indicate more electron
transfer from central metal to the phenyl group. These com-
pounds exhibit comparable pharmacological effects which
may lead to their substitution of harmful synthetic compounds
which may cause side effects acting as threat to metabolism of
humans. Organoantimony(V) compound was found to have
more potential antimicrobial, antiplatelet and antioxidant
activities, which may have therapeutic ventures in future and
it may inhabit the formation of free radicals in the body whichmay damage the basic human metabolism. Due to the
enhanced coordination ability triorganoantimony(V) com-
pounds show different behaviors than their corresponding dio-
rganoantimony(III) compounds.
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